Home » Stocks » RLAY

Relay Therapeutics, Inc. (RLAY)

Stock Price: $44.85 USD 0.00 (0.00%)
Updated Jan 15, 2021 4:00 PM EST - Market closed
After-hours: $44.30 -0.55 (-1.23%) Jan 15, 4:40 PM
Market Cap 3.94B
Revenue (ttm) n/a
Net Income (ttm) n/a
Shares Out 71.25M
EPS (ttm) n/a
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 15
Last Price $44.85
Previous Close $44.85
Change ($) 0.00
Change (%) 0.00%
Day's Open 43.87
Day's Range 42.25 - 45.92
Day's Volume 531,660
52-Week Range 32.81 - 54.03

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 1 week ago

CAMBRIDGE, Mass., Jan. 06, 2021 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY) is scheduled to present at the 39th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12,...

GlobeNewsWire - 1 month ago

Collaboration brings together clinical stage SHP2 and KRAS G12C inhibitors

GlobeNewsWire - 2 months ago

CAMBRIDGE, Mass., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by leveraging u...

Seeking Alpha - 4 months ago

Relay Therapeutics: Heavily Backed Biotech Brains Trust Looks A Long-Term Buy

GlobeNewsWire - 4 months ago

CAMBRIDGE, Mass., Sept. 03, 2020 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by leveragin...

GlobeNewsWire - 4 months ago

CAMBRIDGE, Mass., Aug. 27, 2020 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by leveraging...

GlobeNewsWire - 5 months ago

CAMBRIDGE, Mass., July 20, 2020 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by leveraging...

Business Wire - 6 months ago

TAIPEI, Taiwan--(BUSINESS WIRE)--Oak Stone Limited says SoftBank-backed Relay Therapeutics has soared 75% in its trading debut, expanding its IPO to raise $400 million.

Yahoo Finance - 6 months ago

IPOS to watch: Relay Therapeutics and Trean Insurance Group

Yahoo Finance's Jared Blikre breaks down IPOs Relay Therapeutics and Trean Insurance Group.

Market Watch - 6 months ago

Shares of Relay Therapeutics Inc. RLAY, +67.10% sprinted out of the gate Thursday, after the clinical-stage oncology company's upsized initial public offering priced above the expected range.

Investors Business Daily - 6 months ago

Relay Therapeutics raised $400 million with an initial public offering that priced late Wednesday and surpassed expectations. The Relay Therapeutics IPO will begin trading Thursday morning.

About RLAY

Relay Therapeutics operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology. Its product candidates include RLY-1971, an oral small molecule inhibitor of the protein tyrosine phosphatase Src homology region 2 domain-containing phosphatase-2 (SHP2) that is in Phase 1 dose escalation studies in patients with advanced or metastatic solid tumors; RLY-4008, an oral small molecule selective inhibitor of f... [Read more...]

Industry
Biotechnology
IPO Date
Jul 16, 2020
Stock Exchange
NASDAQ
Ticker Symbol
RLAY
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 6 analysts, the average rating for RLAY stock is "Buy." The 12-month stock price forecast is 55.60, which is an increase of 23.97% from the latest price.

Price Target
$55.60
(23.97% upside)
Analyst Consensus: Buy